About Us
MedGenome is a genomics and clinical data driven diagnostics and drug discovery research company founded in 2013.
We are the market leader in genetic diagnostics in India and offer comprehensive diagnostic solutions to researchers, doctors & hospitals. We have expertise in simultaneous genome sequencing and clinical data analysis to identify genetic mutations across several disease areas.
We operate the largest College of American Pathologists (CAP) accredited Next Generation Sequencing(NGS) lab in South East Asia housing cutting-edge genome sequencing platforms such as Illumina’s NovaSeq, HiSeq X, HiSeq 4000 and2500, MiSeq, etc.
across several disease categories such as paediatrics, neurology, oncology, hematology, endocrinology, nephrology, ophthalmology, etc.
Our Expertise
We have a team of molecular biologists, geneticists, data scientists and bioinformaticians who drive our genomics research. We have successfully built research pipelines addressing immune oncology, biomarker discovery, companion diagnostics and population-based genomic studies that tap the rich Indian diverse genotype.
Innovation
Innovation is a core belief and many of our tests have been developed in-ouse including our comprehensive gene panels. We believe in continuous innovation to help reduce the cost of genetic tests and empower clinicians with actionable clinical insights to provide better outcomes. Our liquid biopsy test OncoTrack for monitoring cancer treatment is the only NGS-based ctDNA test available in India.
We hold several IPs that include Clinical Exome, TB testing, Liquid Biopsy, Tumour Mutation Burden, and many such tests developed for various diseases. We have also launched India centric Carrier Screening Test for couples planning a baby. In the Rare Disease segment, we offer Whole Exome, Clinical Exome and TrioExome sequencing test for identifying gene mutations that cause rare diseases.
MedGenome has entered strategic partnerships to provide best in class tests like Non-Invasive Prenatal Test(NIPT), Infectious Diseases and several other companion diagnostics partnerships with leading pharmaceutical companies.
Accreditations
As a firm believer in quality, MedGenome adheres to the highest international standards when it comes to our services and have obtained the prestigious CAP accreditation for our main lab in Bangalore.
Our Journey

- Series A
funding of
$4m led by Emerge
Ventures
- Single gene
tests - MiSeq - Small gene
panels
- Exome
sequencing –
all genes - Gene Panels
- HiSeq
- Series B funding of $20m led by Sequoia
- NIPT – Non Invasive Prenatal testing
- HLA matching – for transplants
- Genome Asia 100k
- PGS – for IVF
- Series C1 funding $40m led by Sequoia India and Sofina, Zodius Capital & HDFC
- Carrier screening test
- Liquid biopsy
- CAP accreditation, Bangalore lab
- Comprehensive (SNVs, CNVs & fusions)
- Solid & liquid tumor panels
- Coronary Artery Disease (Polygenic risk score)
- Infectious diseases portfolio including TB
- $55m Series C2 funding led by Leapfrog
- Comprehensive TB Portfolio (Routine and Molecular)
- ICMR approved Lab for Covid Testing
- Series C3 funding of $16.5m led by IFC World Bank Group
- Launched Personal Genomics Division - Genessense
- Additional Cancer Tests
- Series D funding of $50m led by Novo Holdings, a leading international life sciences investor
2013
- Series A funding of $4m led by Emerge Ventures
- Single gene tests - MiSeq
- Small gene panels
2014
- Exome sequencing – all genes
- Gene Panels
- HiSeq
2015
- Series B funding of $20m led by Sequoia
- NIPT – Non Invasive Prenatal testing
- HLA matching – for transplants
2016
- Genome Asia 100k
- PGS – for IVF
2017
- Series C1 funding $40m led by Sequoia India and Sofina, Zodius Capital & HDFC
- Carrier screening test
- Liquid biopsy
- CAP accreditation, Bangalore lab
2018
- Comprehensive (SNVs, CNVs & fusions)
- Solid & liquid tumor panels
2019
- Coronary Artery Disease (Polygenic risk score)
- Infectious diseases portfolio including TB
2020
- $55m Series C2 funding led by Leapfrog
- Comprehensive TB Portfolio (Routine and Molecular)
- ICMR approved Lab for Covid Testing
2021
- Series C3 funding of $16.5m led by IFC World Bank Group
- Launched Personal Genomics Division - Genessense
- Additional Cancer Tests
2022
- Series D funding of $50m led by Novo Holdings, a leading international life sciences investor
Awards and Recognition

Business Awards 2022
of Recognition ASK Private Wealth Hurun India Future Unicorn Index 2022
India Diagnostics Award Best Standalone Diagnostics (South)- 2021